Bank Julius Baer & Co
NRIX icon

Bank Julius Baer & Co’s Nurix Therapeutics NRIX Stock Holding History

Bank Julius Baer & Co’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,593
Closed -$1.11M – 856
2021
Q1 		$1.11M Buy
+35,593
New +$1.35M 0.01% 323

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bank Julius Baer & Co's NRIX Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of Nurix Therapeutics (NRIX) in Q2 2021, closing a stake of 35,593 shares — an estimated $1.11M sold.

Bank Julius Baer & Co first reported a position in NRIX in Q1 2021 and held it in 1 quarter. The position peaked at $1.11M in Q1 2021. 103 funds tracked by Wall St. Rank hold NRIX as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining Nurix Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 35,593 Nurix Therapeutics shares in Q2 2021, an estimated $1.11M.
  • Bank Julius Baer & Co first reported a position in Nurix Therapeutics in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's Nurix Therapeutics position peaked at $1.11M in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.